Your browser doesn't support javascript.
loading
Research progress of DNA-PK inhibitors in the cancer treatment / 药学学报
Acta Pharmaceutica Sinica ; (12): 2218-2225, 2023.
Article в Zh | WPRIM | ID: wpr-999132
Ответственная библиотека: WPRO
ABSTRACT
The most toxic DNA damage is DNA double strand breaks (DSBs), which are mainly repaired by non-homologous end joining (NHEJ). DNA-dependent protein kinase (DNA-PK) belongs to phosphatidylinositol-3-kinase-related protein kinase family (PIKK) and plays a key role in NHEJ. DNA-PK is overexpressed in a variety of cancer cells and is related to the occurrence, development and drug resistance of malignant tumors. In this article, the representative DNA-PK inhibitors with anticancer effects are reviewed, in order to provide a reference to discovery novel DNA-PK inhibitors.
Key words
Полный текст: 1 База данных: WPRIM Язык: Zh Журнал: Acta Pharmaceutica Sinica Год: 2023 Тип: Article
Полный текст: 1 База данных: WPRIM Язык: Zh Журнал: Acta Pharmaceutica Sinica Год: 2023 Тип: Article